Splenic artery infusion of IL-2 might allow treatment of melanoma and renal cell cancer with less side effects and greater efficacy
Treatment of stave IV renal cell cancer and melanoma with intravenous interleukin-2 (IL-2) is often limited by side effects, and only a minority of patients obtain sustained remissions. This editorial proposes that infusing IL-2 into the splenic artery will allow much stronger immune activation without systemic side effects, achieving a superior clinical response and enabling treatment of patients currently excluded from IL-2 by medical comorbidities.
Cite this article as: Alisky JM. Splenic artery infusion of IL-2 might allow treatment of melanoma and renal cell cancer with less side effects and greater efficacy. Int J Cancer Ther Oncol 2014; 2(1):020115.
Kondadasula SV, Varker KA, Lesinski GB, et al. Activation of extracellular signaling regulated kinase in natural killer cells and monocytes following IL-2 stimulation in vitro and in patients undergoing IL-2 immunotherapy: analysis via dual parameter flow-cytometric assay. Cancer Immunol Immunother 2008; 57:1137-49.
Yang JC, Sherry RM, Steinberg SM, et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 2003; 21:3127-32.
Schwartzentruber DJ. Guidelines for the safe administration of high-dose interleukin-2. J Immunother 2001; 24:287-93.
Naito K, Pellis NR, Kahan BD. Continuous intrasplenic interleukin-2 combined with antigen-specific chemoimmunotherapy. Arch Surg 1986; 121:1415-20.
Klasa RJ, Silver HK, Kong S. In vivo induction of lymphokine-activated killer cells by interleukin-2 splenic artery perfusion in advanced malignancy. Cancer Res 1990; 50:4906-10.
Lygidakis NJ, Berberabe AE, Spentzouris N, et al. Targeting locoregional immunochemotherapy with new drugs in metastatic liver disease: a promising alternative. Hepatogastroenterology 1998; 45: 2248-51.
Lygidakis NJ, Safioleas M, Sgourakis G, et al. Metastatic melanoma: transplenic immunostimulation-- a new therapeutical alternative for an ever-challenging disease. Hepatogastroenterology 1999; 46:148-56.
Lygidakis NJ. Unresectable metastatic liver disease: new therapeutical alternatives. Hepatogastroenterology 1999; 46 Suppl: 1297-305.
Boura P, Kountouras J, Lygidakis NJ, et al. Transplenic and transtumoral in vivo immunostimulation: effect on cellular immunity parameters. Hepatogastroenterology 1999; 46: 799-803.
Keilholz U, Scheibenbogen C, Brado M, et al. Regional adoptive immunotherapy with interleukin-2 and lymphokine-activated killer (LAK) cells for liver metastases. Eur J Cancer 1994; 30A:103-5.
Okuno K, Ohnishi H, Koh K, et al. Clinical trials of intrasplenic arterial infusion of interleukin-2 (IS-IL-2) to patients with advanced cancer. Biotherapy 1992; 4:257-65.
Okuno K, Ohnishi H, Nakajima I, et al. Complete remission of liver metastases from colorectal cancer by treatment with a hepatic artery infusion (HAI) of interleukin-2-based immunochemotherapy: reports of three cases. Surg Today 1994; 24:80-4.
Abdel-Wahab M, El-Shennawy F, Agha S, et al. Evaluation of cell mediated immunity in advanced pancreatic carcinoma before and after treatment with interleukin-2 (IL-2). Hepatogastroenterology 1999; 46 Suppl 1:1293-6.
Camba L, Aldrighetti L, Ciceri F, et al. Locoregional intrasplenic chemotherapy for hypersplenism in myelofibrosis. Br J Haematol 2001; 114:638-40.
Carrington BM, Thomas NB, Johnson RJ. Selective splenic arteriography for interleukin-2 administration: radiologic complications from the initial 113 procedures. Eur J Radiol 1992; 14:13-7.
Misfeldt ML, Grimm DR. Sinclair miniature swine: an animal model of human melanoma. Vet Immunol Immunopathol 1994; 43:167-75.
Oxenhandler RW, Adelstein EH, Haigh JP, et al. Malignant melanoma in the Sinclair miniature swine: an autopsy study of 60 cases. Am J Pathol 1979; 96:707-20.
Cui J, Chen D, Misfeldt ML, et al. Antimelanoma antibodies in swine with spontaneously regressing melanoma. Pigment Cell Res 1995; 8:60-3.
Pathak S, Multani AS, McConkey DJ, et al. Spontaneous regression of cutaneous melanoma in sinclair swine is associated with defective telomerase activity and extensive telomere erosion. Int J Oncol 2000; 17:1219-24.
This work is licensed under a Creative Commons Attribution 3.0 License.
International Journal of Cancer Therapy and Oncology (ISSN 2330-4049)
© International Journal of Cancer Therapy and Oncology (IJCTO)
To make sure that you can receive messages from us, please add the 'ijcto.org' domain to your e-mail 'safe list'. If you do not receive e-mail in your 'inbox', check your 'bulk mail' or 'junk mail' folders.